Next Article in Journal
Chronic Systemic Exposure to Low-Dose Rotenone Induced Central and Peripheral Neuropathology and Motor Deficits in Mice: Reproducible Animal Model of Parkinson’s Disease
Previous Article in Journal
Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases
Previous Article in Special Issue
The Effect of Nanosystems on ATP-Binding Cassette Transporters: Understanding the Influence of Nanosystems on Multidrug Resistance Protein-1 and P-glycoprotein
Open AccessReview

MicroRNA Nanotherapeutics for Lung Targeting. Insights into Pulmonary Hypertension

1
Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Paseo de Miramón 182, 20014 San Sebastián, Spain
2
CIBER de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain
3
Center for Cooperative Research in Bioscience (CIC bioGUNE), Buiding 800, Science and Technology Park of Bizkaia, 48160 Derio, Spain
4
Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
5
Departamento de Química en Ciencias Farmacéuticas, Universidad Complutense de Madrid, 28040 Madrid, Spain
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(9), 3253; https://doi.org/10.3390/ijms21093253
Received: 5 April 2020 / Revised: 26 April 2020 / Accepted: 30 April 2020 / Published: 4 May 2020
(This article belongs to the Special Issue Nanomedicine, Nanopharmacy and Nanobiomaterials)
In this review, the potential future role of microRNA-based therapies and their specific application in lung diseases is reported with special attention to pulmonary hypertension. Current limitations of these therapies will be pointed out in order to address the challenges that they need to face to reach clinical applications. In this context, the encapsulation of microRNA-based therapies in nanovectors has shown improvements as compared to chemically modified microRNAs toward enhanced stability, efficacy, reduced side effects, and local administration. All these concepts will contextualize in this review the recent achievements and expectations reported for the treatment of pulmonary hypertension. View Full-Text
Keywords: non-coding RNA; microRNA; replacement therapy; antisense-mediated inhibition; mimicRNA; lung targeting; pulmonary disease; pulmonary hypertension; nanoparticle; liposome non-coding RNA; microRNA; replacement therapy; antisense-mediated inhibition; mimicRNA; lung targeting; pulmonary disease; pulmonary hypertension; nanoparticle; liposome
Show Figures

Figure 1

MDPI and ACS Style

Carregal-Romero, S.; Fadón, L.; Berra, E.; Ruíz-Cabello, J. MicroRNA Nanotherapeutics for Lung Targeting. Insights into Pulmonary Hypertension. Int. J. Mol. Sci. 2020, 21, 3253.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop